Researchers at Tel Aviv University (TAU) have uncovered an immune process that may actually help cancer grow rather than fight it, according to a report from The Jerusalem Post. The finding challenges the traditional view that the immune system always works to suppress tumors. Instead, this specific mechanism appears to create conditions that allow cancer cells to thrive.

Key Takeaways

  • TAU researchers identified an immune process that may promote cancer growth.
  • The process involves a type of immune cell that normally fights infection but may be co-opted by tumors.
  • This discovery could lead to new approaches in cancer treatment, especially for patients who do not respond to current immunotherapies.
  • The findings were reported by The Jerusalem Post and are based on laboratory studies.

The Discovery

According to the report, the TAU team studied how certain immune cells behave in the presence of tumors. They found that a particular immune process, which usually helps the body fight off infections, can sometimes be hijacked by cancer. Instead of attacking the tumor, these cells start releasing signals that actually support tumor growth and spread. The researchers believe this may explain why some cancers evade the immune system despite the presence of immune cells nearby.

The study focused on a subset of immune cells known for their role in inflammation. The team observed that when these cells interact with cancer cells, they can switch from a protective role to a harmful one. This switch appears to be driven by molecular signals that the tumor itself releases. The exact details of the signaling pathways were not fully disclosed in the initial report, but the researchers emphasized that the process is distinct from the well-known immune checkpoint mechanisms targeted by current immunotherapies.

How the Immune Process May Fuel Cancer

The immune process identified by the TAU researchers seems to create a microenvironment that is favorable for cancer. The cells involved release substances that promote blood vessel growth, which supplies tumors with oxygen and nutrients. They also suppress the activity of other immune cells that would normally kill cancer cells. This dual effect allows tumors to grow larger and potentially metastasize.

The report notes that this mechanism is not present in all cancers. It appears to be more common in certain aggressive tumor types. The researchers are now investigating whether this process can be blocked with existing drugs or whether new treatments need to be developed. Early laboratory experiments suggest that interfering with the signaling pathway may restore the immune system’s ability to attack the tumor.

Implications for Treatment

If confirmed in further studies, this discovery could have significant implications for cancer therapy. Many patients do not benefit from current immunotherapies, such as checkpoint inhibitors, because their tumors are considered “cold” or non-responsive. The TAU finding suggests that the immune process fueling cancer might be one reason why these treatments fail. Targeting this process could potentially turn cold tumors into hot ones, making them more vulnerable to immune attack.

The researchers caution that the work is still in the preclinical stage. More research is needed to understand exactly how the process works in humans and whether blocking it is safe. However, the study opens a new avenue for drug development. The report from The Jerusalem Post highlights that the TAU team is already collaborating with pharmaceutical companies to explore possible inhibitors.

Frequently Asked Questions

What immune process did the TAU researchers identify?

The researchers identified a specific immune process in which certain cells that normally fight infection instead release signals that promote tumor growth. This process involves inflammatory cells that are co-opted by the cancer to create a supportive environment.

Does this mean the immune system is bad for cancer patients?

No. The immune system still plays a critical role in fighting cancer. This study shows that a specific subset of immune cells can be misdirected by tumors. Most immune cells remain beneficial, and the goal of future treatments would be to stop this harmful process while preserving the protective functions.

How soon could this lead to new cancer treatments?

The research is still in early stages. According to the report, preclinical experiments are ongoing, and collaborations with drug companies have begun. It may take several years before any treatments based on this discovery reach clinical trials.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.